Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Clarithromycin 500mg Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects

NCT02807051
View directory record Official record
Conditions
Drug Interaction Study
Interventions
Pacritinib, Clarithromycin, Pacritinib and Clarithromycin
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 2, 2026, 4:28 PM EDT
Terminated Phase 1 Interventional

Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

NCT03043989
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Cabazitaxel, Clarithromycin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 2, 2026, 4:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Clarithromycin 500 mg Tablets Under Non-Fasting Conditions

NCT00774696
View directory record Official record
Conditions
Healthy
Interventions
clarithromycin 500mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 16, 2008 · Synced Sep 2, 2026, 4:28 PM EDT
Not yet recruiting Phase 3 Interventional

Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans

NCT07104318
View directory record Official record
Conditions
Helicobacter Pylori
Interventions
Bismuth quadruple therapy with optimized PPI, Bismuth quadruple therapy with standard PPI, Clarithromycin triple therapy with optimized PPI, Clarithromycin triple therapy with standard PPI, Standard bismuth quadruple therapy
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 2, 2026, 4:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Clarithromycin 500mg Tablets Under Fasting Conditions.

NCT00774644
View directory record Official record
Conditions
Healthy
Interventions
Clarithromycin 500mg
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 17, 2008 · Synced Sep 2, 2026, 4:28 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma

NCT00538733
View directory record Official record
Conditions
Multiple Myeloma
Interventions
thalomid, lenalidomide, clarithromycin, dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Sep 2, 2026, 4:28 PM EDT
Completed Phase 2 Interventional

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

NCT01745588
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, stem cell, Dexamethasone, Clarithromycin
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
10
States / cities
Basking Ridge, New Jersey • New Brunswick, New Jersey • Commack, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 2, 2026, 4:28 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 2, 2026, 4:28 PM EDT
Terminated Phase 3 Interventional Results available

BiRd vs. Rd as Initial Therapy in Multiple Myeloma

NCT02516696
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Clarithromycin, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 2, 2026, 4:28 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

NCT04302324
View directory record Official record
Conditions
Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
Interventions
Daratumumab SC, Clarithromycin, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 2, 2026, 4:28 PM EDT
Recruiting Phase 4 Interventional

Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)

NCT06396078
View directory record Official record
Conditions
Preterm Premature Rupture of Membrane, Pregnancy, High Risk, Preterm Birth
Interventions
Ceftriaxone 1000 MG, Clarithromycin 500mg, Metronidazole 500 mg, Ampicillin 2 GM Injection, Amoxicillin 250 MG, Azithromycin, Erythromycin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Columbus, Ohio • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 2, 2026, 4:28 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Assessment and Management of Chronic Dyspepsia in Eastern Uganda

NCT04525664
View directory record Official record
Conditions
Helicobacter Pylori Infection, Dyspepsia
Interventions
Clarithromycin 500mg, Amoxicillin 1000 MG, Omeprazole 40 MG, Omeprazole 20 MG Oral Tablet
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Sep 2, 2026, 4:28 PM EDT
Terminated Phase 3 Interventional Results available

Treating H. Pylori in Parkinson's Patients With Motor Fluctuations

NCT00664209
View directory record Official record
Conditions
Parkinson's Disease, Helicobacter Infections, Motor Fluctuations
Interventions
clartihromycin, amoxicillin, and omeprazole, placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 2, 2026, 4:28 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm

NCT03440112
View directory record Official record
Conditions
Parkinson Disease
Interventions
Clarithromycin (Not used as of 4/2020), Placebo (Not used as of 4/2020), Transdermal flumazenil (Added 4/2020), Placebo (Added 4/2020)
Drug
Lead sponsor
Nicolaas Bohnen, MD, PhD
Other
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Sep 2, 2026, 4:28 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin

NCT02387203
View directory record Official record
Conditions
Pseudomyxoma Peritonei, Appendiceal Neoplasms
Interventions
PrevPac (Prevacid, Amoxicillin, Clarithromycin)
Drug
Lead sponsor
Mercy Medical Center
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 2, 2026, 4:28 PM EDT